SEHK:1093Pharmaceuticals
How CSPC’s Oncology Pipeline Milestones and Governance Update Will Impact CSPC Pharmaceutical Group (SEHK:1093) Investors
CSPC Pharmaceutical Group recently reported several oncology milestones, including U.S. FDA clearance for SYH2095 clinical trials and strong Phase Ib/III results for its sirolimus injection HB1901 in advanced malignant PEComa, alongside proposed updates to its articles of association to support hybrid and virtual shareholder meetings.
With first-in-class epigenetic and novel sirolimus-based therapies progressing and antibody-drug conjugate SYS6051 entering trials in both the U.S. and China,...